NEW DELHI :
Panacea Biotec on Tuesday launched single dose and combination medicines of anti-diabetes drug vildagliptin, the patent for which had expired a day earlier, the company said in a statement.
The pharmaceutical company launched the medicine under the brand ViLACT, and will be used to treat uncontrolled type 2 diabetes mellitus, the company said.
ViLACT will be available in four different combinations--50 mg vildagliptin, and three combination doses of 50 mg vildagliptin and varying metformin doses of 500 mg, 850 mg and 1,000 mg.
“The ViLACT brand will be an affordable, high quality medicine in the armamentarium of a physician treating patients with Diabetes," Susheel Umesh, chief executive officer for domestic formulation, said as per the statement.
Annual sales of vildagliptin and its combination drugs was ₹969 crore, the company said quoting data by market research firm AIOCD-AWACS for October.
Vildagliptin is a new oral antidiabetic drug that enhances the response of pancreatic islet cell to glucose, and in turn helps in controlling sugar levels.
Panacea Biotec’s portfolio includes innovative products in therapeutic areas of organ transplantation, nephrology, diabetes, osteoporosis, cardiovascular diseases, vaccines, and oncology. The company is also working on a robust pipeline of generics products that have a high barrier to entry.
The pharmaceutical company sells its products in around 30 countries across the world, including USA, Germany and Russian Federation.
On Tuesday, shares of Panacea Biotec closed 0.8% higher at ₹114.25 on the National Stock Exchange.